5 research outputs found
Follicular Fluid Growth Factors and Interleukin Profiling as Potential Predictors of IVF Outcomes.
International audienceGrowth hormone (GH) has gained attention as an anti-aging compound enhancing oocyte quality. In fact, GH is known to activate intrafollicular metabolic events for oocyte maturation. Insulin growth factor I (IGF1) is another ovarian growth factor that mediates the FSH and GH actions. Cytokines could also increase IVF outcomes. Indeed, IL-6 is a pleiotropic cytokine with multiple cellular effects that can vary based on the physiological environment. IL-6 may also play an important role in follicular development (Yang et al., J Assist Reprod Genet, 2020, 37 (5), 1171-1176). Clinical studies have been performed to explore the potential role of IL-6 in human oocyte maturation and subsequent embryonic development. To date, the answers are not conclusive. During peri-implantation, many cytokines balances are regulated like pro-inflammatory and anti-inflammatory interleukins. The pro-inflammatory properties of IL-17 and its impact on the tumor microenvironment or autoimmune diseases are characterized, but new dimensions of IL-17 activity that promotes embryo implantation are not well explored. In the search for answers, our study compared concentrations of growth factors IGF1, GH, and interleukins IL-6 and IL-17 in the follicular fluid (FF) from 140 women divided into two groups depending on bad (G1) or good prognosis (G2) and investigated the relationships between these FF components' levels and the main parameters of IVF. GH, IGF1, and IL-6 were significantly higher for G2. For GH, it was negatively correlated to patient age and positively correlated to maturity rate and IGF1. Moreover, GH and IGF1 were correlated to the top embryo rate and cumulative pregnancy rate. Regarding IL-6, it was correlated to IGF1 level, endometrium thickness, and implantation rate. As for IL-17, it was only correlated to IL-6. Consequently, all these FF components were predictive of oocyte quality except IL-17. GH seemed to be the best biomarker of this quality
Follicular GH and IGF1 Levels Are Associated With Oocyte Cohort Quality: A Pilot Study
International audienceIntroductionOocyte quality contributes to the development of an optimal embryo and thus a successful pregnancy. The objective of this study was to analyse the association between oocyte cohort quality and the follicular levels of growth hormone (GH), insulin-like growth factor 1 (IGF1), 25-hydroxy vitamin D (25OHD), thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4) and antithyroid antibodies, as a function of intracytoplasmic sperm injection (ICSI) outcomes. Material and methodsWe conducted a prospective comparative pilot study from January 2013 to December 2017. 59 ICSI cycles constituted an abnormal oocyte cohort (n=34 cycles, in which more than 50% of oocytes presented at least one morphological abnormality) and a normal oocyte cohort (n=25 cycles, in which 50% or less of the oocytes presented at least one morphological abnormality). GH, IGF1, 25OHD, TSH, fT3, fT4 and antithyroid antibodies were measured in follicular fluid. ResultsThe fertilisation rate was lower in the abnormal oocyte cohort (65.5% vs. 80%, respectively, p=0.012). Oocytes' proportion with at least one abnormality was 79.4% in the abnormal oocyte cohort and 29.0% in the normal oocyte cohort. The mean number of morphological abnormalities per oocyte was significantly higher in the abnormal oocyte cohort. The follicular levels of GH (4.98 vs. 2.75 mIU/L, respectively; p <0.01) and IGF1 (72.1 vs. 54.2 ng/mL, respectively; p=0.05) were higher in the normal oocyte cohort. There was no association with follicular levels of TSH, fT3, fT4, antithyroid antibodies, or 25OHD. ConclusionOocyte cohort quality appears to be associated with follicular levels of GH and IGF1
Vaginal Tampon Colonization by Staphylococcus aureus in Healthy Women
International audienceTampons recovered from a cohort of 737 healthy women (median age, 32âyears) were analyzed for the presence of Staphylococcus aureus. A total of 198 tampons (27%) were colonized by S. aureus, 28 (4%) by a strain producing toxic shock syndrome toxin 1 (TSST-1). S. aureus was detected more frequently in tampons that did not require an applicator for their insertion (74/233 [32%] versus 90/381 [24%]; odds ratio [OR]â=â1.51 [95% confidence interval, 1.04 to 2.17]) and in women who used an intrauterine device for contraception (53/155 [34%] versus 145/572 [27%]; OR = 1.53 [95% confidence interval, 1.05 to 2.24]). The S. aureus strains isolated from tampons belonged to 22 different clonal complexes (CCs). The most prevalent CC was CC398 agr1 (nâ=â57 [27%]), a clone that does not produce superantigenic toxins, followed by CC30 agr3 (nâ=â27, 13%), producing TSST-1 (24/27 [89%]), the principal clone of S. aureus involved in menstrual toxic shock syndrome (MTSS).IMPORTANCE Menstrual toxic shock syndrome (MTSS) is an uncommon severe acute disease that occurs in healthy menstruating women colonized by TSST-1producing S. aureus who use intravaginal protection, such as tampons and menstrual cups. The catamenial product collected by the protection serves as a growth medium for S. aureus and allows TSST-1 production. Previous studies evaluated the prevalence of genital colonization by S. aureus by vaginal swabbing, but they did not examine tampon colonization. This study demonstrated a high prevalence of tampon colonization by S. aureus and the presence of the CC30 TSST-1 S. aureus clone responsible for MTSS in tampons from healthy women. The results support the vaginal carriage of this lineage in healthy women. In addition, the higher prevalence of S. aureus within tampons that do not require an applicator indicates a crucial role for handwashing before tampon handling to decrease the risk of tampon contamination
Correction: Efficient pathway for men fertility preservation in testicular cancer or lymphoma: a cross-sectional study of national 2018 data
Efficient pathway for men fertility preservation in testicular cancer or lymphoma: a cross-sectional study of national 2018 data
International audienceIn 15â49 years-old men, the main cancers are testicular cancer (TC) and lymphomas (L): freezing of ejaculated sperm is primarily used for male fertility preservation (FP) before cancer treatment. Our objective was to analyze the French FP rate in 15â49 years-old men diagnosed with TC or L in 2018. We designed a national descriptive cross-sectional study of sperm banking rate in men with a diagnosis of TC, Hodgkin L (HL) or non-Hodgkin L (NHL). From the French National Cancer Institute (INCa) 2018 data, we extracted the estimated incidence of TC and L in metropolitan France. From the 2018 activity report of CECOS network (Centers for Study and Banking of Eggs and Sperm), we extracted the number of men with TC or L who banked ejaculated sperm. We estimated the proportion of 15â49 years-old men diagnosed with TC or L who banked sperm. Results Among 15â49 years-old men, INCa estimated 38,048 new cancer diagnoses in metropolitan France in 2018: 2,630 TC and 3,913 L (943 HL and 2,970 NHL). The CECOS network provided data from 26/27 metropolitan centers (96% response rate): 1,079 sperm banking for men with TC, 375 for HL and 211 for NHL. We estimated that the 2018 sperm banking rate in France was 41% for TC, 40% for HL, and 7% for NHL. Conclusions To our knowledge, our paper is the first cross-sectional study with multicenter and national data analyzing FP rate in cancer men: it suggests an efficient pathway for men to FP before cancer treatment, compared to previously published studies. Although sperm banking rate in 15â49 years-old men could definitely be improved, further studies should evaluate the information given to patients before gonadotoxic treatments, the factors associated with the absence of sperm banking and whether this lack of referral induces a loss of chance for these men.Chez les hommes de 15 Ă 49 ans, les principaux cancers sont le cancer du testicule (CT) et les lymhomes (L): la congĂ©lation de spermatozoĂŻdes Ă©jaculĂ©s est utilisĂ©e en premiĂšre intention pour leur prĂ©servation de fertilitĂ© (PF) avant traitement du cancer. Notre objectif Ă©tait dâanalyser le taux de PF chez les hommes de 15 Ă 49 ans diagnostiquĂ©s avec un CT ou un L en 2018 en France. Nous avons rĂ©alisĂ© une Ă©tude nationale transversale descriptive du taux de congelation de spermatozoĂŻdes chez les hommes ĂągĂ©s de 15 Ă 49 ans diagnostiquĂ©s avec un CT, un L de Hodgkin (LH) ou un L non-Hodgkinien (LNH). A partir des donnĂ©es de lâInstitut National du Cancer (INCa) de 2018, nous avons extrait lâincidence estimĂ©e de CT et de L en France mĂ©tropolitaine. A partir des donnĂ©es du bilan dâactivitĂ© 2018 de la Federation Française des CECOS (Centre dâEtude et de Conservation des Oeufs et du Sperme), nous avons extrait le nombre dâhommes avec un CT ou un L qui ont congelĂ© leurs spermatozoĂŻdes. Nous avons enfin estimĂ© la proportion dâhommes de 15 Ă 49 ans diagnostiquĂ©s avec un CT ou un L qui ont congelĂ© leurs spermatozoĂŻdes. RĂ©sultats Chez les hommes de 15 Ă 49 ans, lâINCa a estimĂ© en 2018 38 048 nouveaux cas de cancers diagnostiquĂ©s en France mĂ©tropolitaine en 2018: 2 630 CT et 3 913 L (943 LH et 2 970 LNH). Le rĂ©seau des CECOS a produit les rĂ©sultats issus de 26/27 centres mĂ©tropolitains (taux de rĂ©ponse de 96%): 1 079 congĂ©lations de sperme pour des hommes atteints de CT, 375 pour LH et 211 pour LNH. Nous avons estimĂ© que le taux de congelation de spermatozoĂŻdes de 2018 en France Ă©tait de 41% pour le CT, 40% pour le LH et 7% pour le LNH. Conclusions A notre connaissance, notre travail est la premiĂšre Ă©tude transversale multicentrique de donnĂ©es nationales analysant le taux de PF chez les hommes atteints de cancer: il suggĂšre un parcours patient efficace pour la PF des hommes avant traitement dâun cancer, par rapport aux Ă©tudes prĂ©cĂ©demment publiĂ©es. Bien que le taux de PF chez les hommes puisse certainemen ĂȘtre amĂ©liorĂ©, des Ă©tudes futures devraient Ă©valuer lâinformation donnĂ©e aux patients avant traitement gonadotoxique, les facteurs associĂ©s Ă lâabsence de PF et si le dĂ©faut dâadressage au CECOS induit un perte de chance pour ces hommes. Mots-clĂ©s ChimiothĂ©rapie, RadiothĂ©rapie, OncofertiitĂ©, Azoospermia, Paternit